Savara Inc financial data

Symbol
SVRA on Nasdaq
Industry
Pharmaceutical Preparations
Location
6836 Bee Cave Road, Building 3, Suite 201, Austin, TX
State of incorporation
DE
Fiscal year end
December 31
Former names
Mast Therapeutics, Inc. (to 4/25/2017), ADVENTRX PHARMACEUTICALS INC (to 3/1/2013), BIOKEYS PHARMACEUTICALS INC (to 5/15/2003)
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.5K % -33.4%
Debt-to-equity 28.8 % -6.52%
Return On Equity 10.6K % +105%
Return On Assets -45.8 % -43.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 165M shares +21.8%
Common Stock, Shares, Outstanding 138M shares +21.1%
Entity Public Float 410M USD +158%
Common Stock, Value, Issued 140K USD +20.7%
Weighted Average Number of Shares Outstanding, Basic 183M shares +19.5%
Weighted Average Number of Shares Outstanding, Diluted 183M shares +19.5%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 20.2M USD +64.2%
Operating Income (Loss) -81.3M USD -77.8%
Net Income (Loss) Attributable to Parent -75.3M USD -76.4%
Earnings Per Share, Basic -0.42 USD/shares -50%
Earnings Per Share, Diluted -0.42 USD/shares -50%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 23.9M USD +4.92%
Assets, Current 128M USD +18.3%
Property, Plant and Equipment, Net 236K USD -10.6%
Operating Lease, Right-of-Use Asset 400K USD +300%
Other Assets, Noncurrent 1.11M USD +24.6%
Assets 140M USD +16.6%
Accounts Payable, Current 3.39M USD +35.3%
Employee-related Liabilities, Current 1.83M USD +30.2%
Accrued Liabilities, Current 7.9M USD +134%
Liabilities, Current 11.3M USD +91.8%
Operating Lease, Liability, Noncurrent 200K USD +300%
Other Liabilities, Noncurrent 169K USD +745%
Liabilities 37.9M USD +18.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -880K USD -42.2%
Retained Earnings (Accumulated Deficit) -436M USD -20.9%
Stockholders' Equity Attributable to Parent 102M USD +16%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -880K USD -42.2%
Liabilities and Equity 140M USD +16.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -20.6M USD -71.7%
Net Cash Provided by (Used in) Financing Activities 49K USD +88.5%
Net Cash Provided by (Used in) Investing Activities 10.8M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 138M shares +21.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.8M USD +45.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 536K USD +15.5%
Deferred Tax Assets, Valuation Allowance 73.9M USD +45.2%
Deferred Tax Assets, Gross 74.8M USD +46%
Operating Lease, Liability 344K USD +213%
Payments to Acquire Property, Plant, and Equipment 10K USD +150%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -75.5M USD -78.6%
Lessee, Operating Lease, Liability, to be Paid 390K USD +233%
Property, Plant and Equipment, Gross 2.28M USD +15.6%
Operating Lease, Liability, Current 200K USD +233%
Lessee, Operating Lease, Liability, to be Paid, Year Two 160K USD +196%
Lessee, Operating Lease, Liability, to be Paid, Year One 143K USD +127%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 46K USD +557%
Lessee, Operating Lease, Liability, to be Paid, Year Three 87K USD
Deferred Tax Assets, Operating Loss Carryforwards 44.7M USD +14.8%
Preferred Stock, Shares Authorized 1M shares 0%
Share-based Payment Arrangement, Expense 6.81M USD +140%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%